MedTrace Logo

Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

NCT02172885 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-10-03

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

Conditions

Interventions

BIOLOGICAL

Mesenchymal Stem Cells

Mesenchymal Stem Cell Infusions

Sponsors & Collaborators

  • Hospital Universitario Getafe

    collaborator OTHER

  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain

    collaborator OTHER

  • Hospital de Cruces

    lead OTHER

Principal Investigators

  • Clara I. Rodríguez, Ph. D. · BioCruces Health Research Institute/Cruces University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172885 on ClinicalTrials.gov